RegeneRx Biopharmaceuticals IncOTCQB:RGRX
- LAST PRICE0.0399
- TODAY'S CHANGE (%)0.0050 (14.1631%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.0300 / 0.0350
- Day Range
- 52 Week Range
- Volume48,470
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGRX |
|---|---|---|
| 09:38 ET | 200 | 0.03 |
| 09:52 ET | 100 | 0.03005 |
| 09:54 ET | 100 | 0.0399 |
| 10:17 ET | 10000 | 0.0399 |
| 10:19 ET | 12800 | 0.0399 |
| 03:43 ET | 25070 | 0.03 |
| 03:45 ET | 100 | 0.0399 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
RegeneRx Biopharmaceuticals Inc | 5.0M | -3.4x | --- |
Axim Biotechnologies Inc | 5.0M | -0.6x | --- |
Allarity Therapeutics Inc | 5.0M | 0.0x | --- |
Quoin Pharmaceuticals Ltd | 5.0M | -0.1x | --- |
Artelo Biosciences Inc | 4.9M | -0.5x | --- |
GB Sciences Inc | 4.9M | -0.8x | --- |
Company Information
RegeneRx Biopharmaceuticals, Inc. (RegeneRx) is a biopharmaceutical company. The RegeneRx is focused on the development of a therapeutic peptide Thymosin beta 4(Tb4) for tissue and organ protection, repair, and regeneration. RegeneRx operates in the development and marketing of Tb4, an amino acid peptide. Tb4 is a synthetic copy of a naturally occurring 43-amino acid peptid originally isolated from bovine thymus glands. The Company's product candidates in clinical development includes RGN-259, RGN-352, and RGN-137. The Company's RGN -259 is a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology. RGN-352 is an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases. Its RGN-137 is a topical gel for dermal wounds and reduction of scar tissue.
Contact Information
- Headquarters
- 15245 SHADY GROVE ROAD, SUITE 470ROCKVILLE, MD, United States 20850
- Phone
- 301-208-9191
- Fax
- 301-208-9194
Executives
- Chairman of the Board, Founder, Chief Scientific Officer
- Allan Goldstein
- President, Chief Executive Officer, Director
- J. Finkelstein
- Director
- Alessandro Noseda
- Independent Director
- Mauro Bove
- Independent Director
- Raymond Elsey
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $5.0M |
|---|---|
Revenue (TTM) | $76.8K |
Shares Outstanding | 143.5M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.49 |
EPS | $-0.01 |
Book Value | $-0.02 |
P/E Ratio | -3.4x |
Price/Sales (TTM) | 65.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -1,775.74% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
